» Articles » PMID: 28686863

The Evolving Roles of Human IPSC-Derived Cardiomyocytes in Drug Safety and Discovery

Overview
Journal Cell Stem Cell
Publisher Cell Press
Specialty Cell Biology
Date 2017 Jul 8
PMID 28686863
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.

Citing Articles

Human induced pluripotent stem cell-cardiomyocytes for cardiotoxicity assessment: a comparative study of arrhythmiainducing drugs with multi-electrode array analysis.

Park N, Park Y, Choi J, Choi H, Moon S, Park S Korean J Physiol Pharmacol. 2025; 29(2):257-269.

PMID: 39972675 PMC: 11842287. DOI: 10.4196/kjpp.24.413.


Comparative cardiotoxicity assessment of bisphenol chemicals and estradiol using human induced pluripotent stem cell-derived cardiomyocytes.

Cooper B, Salameh S, Posnack N Toxicol Sci. 2024; 198(2):273-287.

PMID: 38310357 PMC: 10964748. DOI: 10.1093/toxsci/kfae015.


Endothelial cell dysfunction in cardiac disease: driver or consequence?.

Allbritton-King J, Garcia-Cardena G Front Cell Dev Biol. 2023; 11:1278166.

PMID: 37965580 PMC: 10642230. DOI: 10.3389/fcell.2023.1278166.


Spatially resolved multiomics of human cardiac niches.

Kanemaru K, Cranley J, Muraro D, Miranda A, Ho S, Wilbrey-Clark A Nature. 2023; 619(7971):801-810.

PMID: 37438528 PMC: 10371870. DOI: 10.1038/s41586-023-06311-1.


Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy.

Pan Z, Liang P Handb Exp Pharmacol. 2023; 281:209-233.

PMID: 37421443 DOI: 10.1007/164_2023_663.